The ability of MG1 to selectively kill IFN-defective cancer cells has proven feasible in animal models and is now being studied in patients with metastatic solid tumors and non–small-cell lung cancer (clinical trials identifiers NCT02285816 and NCT02879760). Here, MUC5B is linked to cancer.